Skip to content

Author

M. Noronha

We have 2 of 49 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Treatment Effect Discrepancy Between PFS and OS in Antibody-Drug Conjugate Trials for Metastatic Breast Cancer: A Meta-Epidemiologic Analysis.

OBJECTIVE The validity of progression-free survival (PFS) as a surrogate for overall survival (OS) in the antibody-drug conjugate (ADCs) era remains uncertain. We evaluated the association between treatment effects on PFS and OS in randomized trials of ADCs for metastatic breast cancer (mBC) and explored the surrogate...

L. F. Costa de Almeida, A. Cappellaro, M. Noronha et al. · 0 citations
Review Open access Aug 2026

Antibody-drug conjugates and beyond in platinum-resistant ovarian cancer: A comprehensive review of emergent strategies

Continued translational research is therefore essential to identify predictive biomarkers and to optimize novel combination strategies to overcome resistance, as well as the integration of dynamic biomarkers and quantitative tools to define optimal treatment sequencing and improve patient outcomes in this challenging d...

M. Noronha, L. F. Costa de Almeida, V. Costa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.